Contact
English

Inogen, Inc. - Provider site

  • English
  • About
  • Why Inogen
    • Overview
    • Oxygen Therapy
    • Cost of Ownership
    • Clinical Evidence Summary
  • Solutions
    • Overview
    • Provider Benefits
    • Patient Benefits
  • Products
    • Overview
    • G3 System
    • G4 System
    • G5 System
    • Rove 4 System
    • Rove 6 System
  • Support
    • Overview
    • Inogen® Connect
    • Returns & Exchanges
    • Product Materials and Videos
    • Testing O2 Purity
    • Discontinued Product User Manuals
    • SNDS
    • Compliance
    • US MAP Policy
  • Contact

Select Langauge

  • English
  • Italiano
  • Deutsch
  • Ελληνικά
  • Nederlands
  • العربية
  • Norsk
  • Português
  • Svenska
  • 영어
  • Español
  • Français

This website uses cookies for analytics and providing you the best user experience. Our Privacy Policy explains what data we collect from cookies, how they are used and opt-out information. By clicking "I agree" you consent to our use of cookies.

I agree

Clinical Evidence Summary

PORTABLE OXYGEN CONCENTRATORS

Clinical Evidence Summary

Modern portable oxygen concentrators (POCs) have been shown as effective supplemental oxygen. Read the full studies below that demonstrate the impact of portable oxygen concentrators and pulse dose oxygen delivery for patients’ long-term oxygen therapy.

Health and Economic Impact of Different Long-Term Oxygen Therapeutic Strategies in Patients with Chronic Respiratory Failure

This retrospective comparative analysis included adult patients with chronic respiratory insufficiency and failure (CRF) upon a first delivery of LTOT between 2014 and 2019 and followed until December 2020, based on the French national healthcare database SNDS.

Stanislav Glezer, Gregoire Mercler, Jean-Marc Coursler, Nicoleta Petrica, Marla Pini, Abhijith Pg

THE RELATIVE MORTALITY RISK WAS

19% LOWER

in the High Mobility POC group, as compared to the Low Mobility POC group. The high mobility POC group included patients equipped with devices with battery run time greater than 5 hours, which used Inogen devices. The Low Mobility POC group, which included patients equipped with devices with battery run time lower than 5 hours, used non-Inogen POCs.

Better survival and lower mortality were associated with the POC and HM groups.

  • POC (alone or in combination) was better than other modalities (stationary concentrator, tank, liquid).

  • HM group (higher mobility/higher autonomy POC, i.e., Inogen device) better than LM group (lower mobility/lower autonomy POC, i.e., non-Inogen device).

Read the published paper

Patient Use Patterns of Portable Oxygen Concentrators

A retrospective analysis was conducted to assess portable oxygen concentrator (POC) usage among patients who used an Inogen One G5 POC in the United States.

Glezer et al. Patient use patterns of portable oxygen concentrators. Pulmonary Therapy 2024;10(1):123-132.

POC USERS ARE MOBILE

42%

of the time when using battery power.

Data collected from this study showed that patients frequently take advantage of POC portability, being mobile almost 42% of the time when using battery power.

Read the published paper

Contemporary Portable Oxygen Concentrators and Diverse Breathing Behaviors

Three contemporary devices (Inogen One G3, ResMed Mobi, and Philips Respironics SimplyGo Mini) were bench-evaluated across three simulated breathing behaviors: activity, rest, & oronasal breathing during sleep.

A Bench Comparison by Martin

Respiratory flow and oxygen flow for a single breath during pulsed dose oxygen delivery. Oxygen is potentially ‘useful’ to the patient if delivered within the ‘alveolar’ tidal volume. Wastage of oxygen may occur if the oxygen pulse flow exceeds inspiratory flow, depending on the prevailing conditions.

READ THE PUBLISHED PAPER

Long Term Domiciliary Oxygen Therapy in Chronic Hypoxic Cor Pulmonale Complicating Chronic Bronchitis and Emphysema

This trial was planned to determine if oxygen, given for 15 hours in a day, over a three year period, could reduce mortality and improve exercise tolerance and working capacity.

Report of the Medical Research Council Working Party

Long-term oxygen therapy, given for 15 hours/day, can reduce mortality over three years in both men and women with severe hypoxic cor pulmonale complicating chronic bronchitis and emphysema.

Indicators such as general improvement in the sense of wellbeing, improved appetite, and general alertness were frequently found in those patients treated with oxygen.

Read the published paper
Inogen, Inc
  • About
  • About Inogen
  • Contact
  • Support
  • Why Inogen
  • Overview
  • Oxygen Therapy
  • Cost of Ownership
  • Clinical Evidence Summary
  • Solutions
  • Overview
  • Provider Benefits
  • Patient Benefits
  • Products
  • Overview
  • G3 System
  • G4 System
  • G5 System
  • Rove 4 System
  • Rove 6 System
  • Support
  • Overview
  • Inogen® Connect
  • Returns & Exchanges
  • Product Materials and Videos
  • Testing O2 Purity
  • Discontinued Product User Manuals
  • SNDS
  • Compliance
  • US MAP Policy
© 2025 Inogen, Inc. All Rights Reserved.
Privacy Policy Sitemap

Certain products or functionality may not be available in all markets. Please check with your Inogen representative for availability.